- July 2019
- October 2019
- December 2019
- September 2020
- April 2026
-
company founded
Company founded by Dr. Lieping Chen (Yale University) to pioneer the next generation of immunotherapies to treat cancer and autoimmune disease and to collaborate with academic and industry partners, addressing significant unmet medical needs and providing patients worldwide with access to new innovations.
-
first licensing deal
Completed our first licensing deal with immuno-oncology pioneers Drs. Lieping Chen (Yale University) and Yuwen Zhu (University of Colorado, Denver), obtaining world-wide rights to CD93, a novel therapeutic target resulting from pioneering research into malignant tumor vasculature, aiming to turn the tumor microenvironment (TME) from immunosuppressive to immunostimulatory and to enhance the efficacy of immunotherapies and chemotherapeutic agents.
-
Licensed second target
Licensed second target (undisclosed) based on the research of Dr. Lieping Chen to advance our mission and focus on autoimmune disease.
-
830 Winter Street Office
Moved into 17,000 square foot laboratory and office space at current headquarters at 830 Winter Street in Waltham, Massachusetts.
-
Move to 300
Moved into 300 Bear Hill Rd in Waltham, Massachusetts.